Telo Genomics announced that its proprietary blood-based TELO-MRD assay detected residual multiple myeloma cells in 92.9% of matched samples, outperforming the standard bone marrow EuroFlow next-generation flow cytometry which detected 54.8%. The TELO-MRD test not only counts residual cancer cells but also profiles their genomic instability, potentially offering better relapse risk assessment. The company plans to further develop and commercialize this non-invasive test by the end of 2027, aiming to improve personalized treatment for multiple myeloma patients.
Telo Genomics clinical research results provide context for readers. For those following the health sector, 35 of 91 US health stocks rose and 48 fell on Pluang. ENVB was priced at USD 1.46 with a -2.67% change, INO at USD 1.21 with +2.54%, and ABCL at USD 11.00 with -1.52%, as of Sep 15, 2026 16:41 WIB.
The ERShares Private-Public Crossover ETF (XOVR) achieved a 5.64% cumulative NAV return from the SpaceX IPO on June 12, 2026, through September 4, 2026, outperforming major growth indexes like the Russell 1000 Growth and Nasdaq 100. Since its relaunc...
Intel's stock has surged 291.64% over the past year, driven by strong AI-focused CPU demand, progress in its 18A node, and a revitalized foundry business. Despite recent volatility and concerns over a $15 billion stock offering and ongoing foundry lo...
Mastercard's Dreamonomics report reveals that 68% of small and medium-sized enterprises (SMEs) prioritize stability and predictability rather than rapid growth, reflecting a shift in business mindset amid economic uncertainty. SMEs use an average of ...
Oracle announced a $40 billion financing plan for fiscal 2027 to support its rapid AI datacenter expansion, which outpaces its current cash flow. Despite strong demand with cloud infrastructure revenue up 121% year-over-year and over $30 billion in n...
Nvidia shares fell over 8% in a week amid concerns of an AI slowdown, but one investor is increasing their position, citing strong fundamentals and growth prospects. Nvidia reported Q2 FY2027 revenue of $96.22 billion, up 105.8% year-over-year, with ...
